ArticleScientific reports2025
Exosomal LncRNA SCAMP1-AS1 enhances osteosarcoma malignancy by regulating the LKB1-AMPK signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophage plasticity in the osteosarcoma tumor microenvironment: opportunities and challenges for immunotherapy.Journal of cancer research and clinical oncology · 2026Review
- Isoforms in action: The impact of transcript diversity in phenotype.Genetics and molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Exosomes are extracellular vesicles that facilitate communication among cells by exchanging signaling biomolecules with adjacent cells. Among the diverse signaling biomolecules, long noncoding RNAs (lncRNAs) can be selectively packaged into exosomes to influence cancer onset and progression through various mechanisms. This study aimed to explore the role of exosomal lncRNA SCAMP1-AS1 in osteosarcoma (OS). The expression of SCAMP1-AS1 was determined by quantitative reverse-transcription polymerase chain reaction in OS samples, and its role in OS was investigated by performing Cell Counting Kit-8, EdU, and Transwell assays. The characterization of exosomes derived from OS cell lines was conducted by transmission electron microscopyand Western blotting of CD9 and CD81. The effects of exosomes and exosomal SCAMP1-AS1 on OS cells were also evaluated in a series of cell assays. Furthermore, key molecules in the liver kinase B1-adenosine monophosphate-activated protein kinase (LKB1-AMPK) signaling pathway were analyzed by through Western blotting. The results revealed high SCAMP1-AS1 expression in OS, and its silencing in OS cells led to a reduction in cell proliferation, migration, and invasion. The OS cell-derived-exosomes increased the malignant characteristics in the target OS cell lines. Notably, exosomes obtained from OS cells in which SCAMP1-AS1 was silenced effectively counteracted the tumor-promoting effects typically observed with OS-derived exosomes on cocultured target OS cells by activating the LKB1-AMPK signaling pathway. These results demonstrate that exosomal SCAMP1-AS1 serves as a tumor promoter in OS by regulating the LKB1-AMPK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.